Sign in

AMBI on NASDAQ

Ambit Biosciences

Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI".3 It was founded in 2000.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Jan 1, 2000Founded1

Compare with another stock.

  • TickerAMBI on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersSan Diego1
  • Websitewww.ambitbio.com
  • Incorporated inDE4
  • Business address11080 Roselle Street, San Diego, Ca 921214
  • Filer categorySmaller reporting company4

See how the biggest companies compare on our leaderboards

Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.3

What it owns

What Ambit Biosciences reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.6M6 Dec 31, 2013$6.0M6 Dec 31, 2012−22.4%
Accumulated depreciation$3.8M6 Dec 31, 2013$5.4M6 Dec 31, 2012−28.9%
Property and equipment, net$785.0K6 Dec 31, 2013$560.0K6 Dec 31, 2012+40.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$71.2M6 Dec 31, 2013$17.5M6 Dec 31, 2012+307.2%

Leadership

Who has led Ambit Biosciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael A. Martino2013–2014

President

  1. Michael A. Martino2013–2014

Chief financial officer

  1. Alan Fuhrman2013–2014
20052010201520202025
Board members and other officers (12)

Products and brands

Products

As of March 2014, three products were under development, of which quizartinib was their lead drug candidate.

Business model

In June 2010, Ambit completed a Series D-2 round of equity financing, raising $30 million in new capital. The investor syndicate was led by Apposite Capital LLP and included existing investors such as Perseus-Soros Biopharmaceutical Fund, OrbiMed Advisors, Forward Ventures, Roche Venture Fund, MedImmune Ventures, GIMV, GrowthWorks, Genechem, Radius Ventures, NovaQuest and Horizon Technology Finance.

As of March 2014, Ambit sought to develop new therapeutics through internal, proprietary research, which is evidenced by their pipeline of three products consisting entirely of internally developed therapeutics. Further, Ambit aimed to be a full life cycle pharmaceutical company by conducting discovery, development and further commercialization of therapeutics.

Among the firms who invested heavily in Ambit prior to its initial public offering was Foresite Capital in January 2013.

Read the full text

In November 2014, Ambit was acquired by Daiichi Sankyo. The prime asset that drove this deal was Ambit's quizartinib (AC220).

From Wikipedia’s article on Ambit Biosciences, shared under CC BY-SA 4.0.5

Former names

  • AVENTA BIOSCIENCES CORPJun 12, 2002 to Jun 12, 20024

Timeline

  1. May 15, 2013New chief executive Michael A. Martino becomes CEO7
  2. May 2013Went public Listed on NASDAQ1
  3. Jan 1, 2000Founded Founded1

SEC filer profile

How Ambit Biosciences is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAMBIT BIOSCIENCES CORP2
  • CIK0001131543
  • Employer ID (EIN)33-09096482
  • Filer statusSmaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address11080 Roselle Street, San Diego, CA 921212
  • Phone85833421002
  • Shares outstanding18,000,122 as of Jul 31, 201420
  • Public float$34.7M as of Jun 30, 20136
  • On EDGAR sinceJun 12, 20022
  • Filings171 in all: 4 (45), 8-K (17), 3 (16), SC 13G (8), D (7), REGDEX (7), S-1/A (6), SC 13G/A (5)2
    All 41 form types

    10-Q (4), CORRESP (4), SC 13D (4), SC TO-C (4), UPLOAD (4), EFFECT (3), SC 14D9/A (3), SC TO-T/A (3), SC14D9C (3), S-1 (2), S-8 (2), S-8 POS (2), SC 13D/A (2), 10-K (1), 10-K/A (1), 15-12B (1), 25-NSE (1), 3/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DEF 14A (1), DRS (1), DRSLTR (1), FWP (1), POS AM (1), REGDEX/A (1), RW (1), S-3 (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 20, 2014
    Quarterly report (10-Q) Aug 12, 2014
    Proxy statement (DEF 14A) Apr 9, 2014
    Latest 8-K (8-K) Nov 17, 2014

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20